Treatment goals for Ivy, who is diagnosed with Generalized Anxiety Disorder (GAD),

QUESTION

Answer the following questions in five well-developed paragraphs, integrating five evidence-based resources to include clinical practice guidelines and the course textbook. Provides clear examples supported by course content and references, and citations

Cites three or more references, using at least three new scholarly resources within five years from 2023, including clinical practice guidelines, as well as the course textbook. That were not provided in the course materials. Please provide an exact dose for the chosen medications, route of administration, and frequency.

Woo, T. M., & Robinson, M. V. (2020). Pharmacotherapeutics for advanced practice nurse prescribers (5th ed.). Philadelphia, PA: F.A. Davis Company.

Ivy, age 23, is a white woman who graduated from college last year. She began working as an accountant one month after graduating. Approximately two months ago, she moved into a two-bedroom apartment with another woman who works at the same accounting firm. She states that her roommate recommended that she sees a doctor to find out if she has anemia or “some sort of fatigue syndrome.” She states that she has felt “restless” and “on edge” for most of the past nine months. She becomes easily fatigued and irritable and has difficulty concentrating and falling asleep. She states that sometimes her mind “just goes blank,” and she is worried that her work performance is no longer excellent.

She reports that all her life she had good grades in school and was very successful in everything she attempted. Although she has been “a worrier from the day I was born,” now she worries more than she ever has and feels nervous “all the time.” Ivy reports that she has a good relationship with her boyfriend, but they do not get to see each other very often because he is attending graduate school 100 miles away. She reports having a satisfying sexual relationship with him. She denies having any problems with relationships with her parents, roommate, or peers. She denies having any financial worries unless she is fired from her job for poor work performance. She reports that she has always been healthy and has taken good care of herself. The only medication she takes is birth control pills, which she has taken for the past four years without any adverse effects.

Diagnosis: Generalized Anxiety Disorder

1. List specific treatment goals for Ivy.

2. What drug therapy would you prescribe? Why?

3. What are the parameters for monitoring the success of the therapy?

4. Describe specific patient monitoring based on the prescribed therapy.

5. List one or two adverse reactions for the selected agent that would cause you to change therapy.

6. What would be the choice for second-line therapy?

7. What dietary and lifestyle changes should be recommended for this patient?

8. Describe one or two drug-drug or drug-food interactions for the selected agent.

ANSWER

Treatment goals for Ivy, who is diagnosed with Generalized Anxiety Disorder (GAD), should focus on reducing anxiety symptoms, improving overall well-being, and enhancing daily functioning. Specific treatment goals may include

Decreasing anxiety levels: The primary objective is to alleviate Ivy’s feelings of restlessness, nervousness, and being on edge. This can be achieved by reducing anxiety-related symptoms such as fatigue, irritability, difficulty concentrating, and sleep disturbances.

Enhancing coping skills: Helping Ivy develop effective coping strategies to manage her worries and stress can contribute to improved emotional regulation and adaptive functioning. This may involve teaching relaxation techniques, mindfulness practices, and cognitive restructuring to challenge negative thought patterns.

Improving work performance: Addressing Ivy’s concerns about her work performance is crucial. The treatment plan should aim to restore her ability to concentrate, maintain productivity, and regain her previous level of excellence.

Considering Ivy’s symptoms and the recommended treatment goals, the drug therapy of choice for GAD is selective serotonin reuptake inhibitors (SSRIs). SSRIs, such as escitalopram, have been found to be effective in reducing anxiety symptoms and improving overall functioning in individuals with GAD. The initial dose of escitalopram is typically 10 mg per day, administered orally. The dosage can be adjusted based on individual response and tolerability. Escitalopram is a preferred option due to its efficacy, favorable side effect profile, and lower risk of drug interactions compared to other antidepressants.

The success of therapy can be monitored through regular assessments of Ivy’s anxiety symptoms, functioning, and overall well-being. Standardized rating scales such as the Hamilton Anxiety Rating Scale (HAM-A) or the Generalized Anxiety Disorder 7-item scale (GAD-7) can be used to measure the severity of anxiety symptoms and track changes over time. Monitoring should also include regular follow-up visits to assess treatment response, discuss any side effects, and provide additional support and counseling as needed.

Patient monitoring based on the prescribed therapy should involve ongoing assessment of medication adherence, evaluation of treatment response, and monitoring for potential adverse reactions. It is important to closely monitor Ivy’s response to the medication during the first few weeks of treatment, as SSRIs may initially worsen anxiety symptoms before improvement occurs. Close communication and follow-up with Ivy will help ensure proper dosage adjustments and management of any emerging side effects.

Potential adverse reactions of escitalopram include gastrointestinal disturbances, such as nausea, diarrhea, and abdominal discomfort. If Ivy experiences severe or persistent gastrointestinal side effects, alternative treatment options or dose adjustments may be considered. Additionally, SSRIs may rarely cause an increase in anxiety symptoms or agitation, which should be closely monitored. If these adverse reactions occur and significantly affect Ivy’s well-being, alternative treatment strategies or consultation with a mental health specialist should be considered.

If first-line therapy with escitalopram does not adequately address Ivy’s symptoms or if she experiences intolerable side effects, second-line therapy options for GAD may include serotonin-norepinephrine reuptake inhibitors (SNRIs) such as venlafaxine or other antidepressant agents such as benzodiazepines. However, benzodiazepines should be used cautiously and for short-term management due to their potential for dependence and abuse.

In addition to pharmacotherapy, incorporating dietary and lifestyle changes can be beneficial for managing anxiety. Encouraging Ivy to adopt a balanced diet, engage in regular physical activity, practice relaxation techniques, and get adequate sleep can contribute to overall well-being and reduce anxiety symptoms. Avoiding or limiting the consumption of caffeine and alcohol, which can exacerbate anxiety symptoms, should also be recommended.

One potential drug-drug interaction to consider with escitalopram is its combination with monoamine oxidase inhibitors (MAOIs), which can lead to serotonin syndrome. Therefore, a washout period should be observed when transitioning from an MAOI to escitalopram. Another interaction to be cautious about is the use of nonsteroidal anti-inflammatory drugs (NSAIDs) or anticoagulants concurrently with escitalopram, as it may increase the risk of bleeding. Close monitoring of bleeding parameters should be conducted if co-administration is necessary.

In conclusion, the treatment goals for Ivy’s Generalized Anxiety Disorder involve reducing anxiety symptoms, improving coping skills, and enhancing work performance. The recommended drug therapy is escitalopram, a selective serotonin reuptake inhibitor, with close monitoring of treatment response and potential adverse reactions. Second-line therapy options may be considered if the initial treatment is ineffective or poorly tolerated. Lifestyle modifications, such as adopting a balanced diet and engaging in relaxation techniques, should be encouraged. It is essential to consider potential drug-drug interactions, such as co-administration with MAOIs or NSAIDs, to ensure patient safety and optimize treatment outcomes.